MOXD1 is a gate-keeper of organ homeostasis and functions as a tumor-suppressor in neuroblastoma
Fredlund, E.; Andersson, S.; Hilgert, E.; Alvarez-Hernan, G.; Monferrer, E.; Karakaya, S.; Gregor, T.; Loontiens, S.; Bek, J. W.; Lecomte, E.; Magnusson, E.; Miltenyte, E.; Cabirol, M.; Kyknas, M.; Engstrom, N.; Arsenian Henriksson, M.; Hammarlund, E.; Noguera, R.; Speleman, F.; van Nes, J.; Mohlin, S.
Show abstract
Neuroblastoma is a childhood cancer believed to result from dysfunctional development. Its origin during embryogenesis remains poorly understood. The lack of appropriate models has hindered in-depth mapping of tumor-driving events. Here, we identify a novel tumor-suppressor gene that predicts poor survival in high-risk disease, by applying bulk and single cell RNA sequencing data of neuroblastoma and human fetal adrenal glands. Trunk neural crest-specific MOXD1 discriminates cell populations during normal and tumor development, with implications for deciphering neuroblastoma cell origin. We created an embryonic conditional knockout model and show that cell type-specific loss of MOXD1 leads to disrupted organ homeostasis and failed adrenal gland formation, home for neuroblastoma. We show that MOXD1 is a tumor suppressor gene in zebrafish, chick, and mice in vivo models. One-Sentence SummaryNeural crest-specific MOXD1 is a de novo tumor-suppressor gene in childhood cancers arising during embryogenesis.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- NAB2-STAT6 drives an EGR1-dependent neuroendocrine program in Solitary Fibrous Tumors 95%
- VLA-4 suppression by senescence signals regulates meningeal immunity and leptomeningeal metastasis 95%
- Dual role of FOXG1 in regulating gliogenesis in the developing neocortex via the FGF signalling pathway. 94%
Similar papers in this journal
Similar papers in this journal
- NKX2-1 controls lung cancer progression by inducing DUSP6 to dampen ERK activity 95%
- Isoform-specific functions of Numb in breast cancer progression, metastasis and proteome remodeling. 95%
- Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers 94%
Similar papers in this journal
- Nemo-like kinase disrupts nuclear import and drives TDP43 mislocalization in ALS 95%
- The cholesterol biosynthesis enzyme FAXDC2 couples Wnt/beta-catenin to RTK/MAPK signaling 94%
- SLIT2-ROBO signaling in tumor-associated microglia/macrophages drives glioblastoma immunosuppression and vascular dysmorphia 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.